Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 17 of 24, showing 10 Applications out of 238 total, starting on record 161, ending on 170

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

161.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
28-07-2021 View

162.

ECCT/21/06/01   ACTIV-2/A5401
    ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_   
Principal Investigator(s)
1. Charles Meja Kwobah
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
01-11-2021 View

163.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
13-05-2021 View

164.

ECCT/23/04/04   AGREE
    Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
1. Ahero County Hospital (Kisumu county)
2. Alupe sub-county Hospital (Busia county)
3. Siaya County Referral Hospital (Siaya county)
 
24-08-2023 View

165.

ECCT/21/02/03   VAC078
    A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria.   
Principal Investigator(s)
1. Mainga Patience Mayeso Hamaluba
2. Jean Bosco Ouedraogo
3. Halidou Tinto
4. Alassane Dicko
5. Ally Olotu
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
02-04-2021 View

166.

ECCT/21/03/02   PB-SAM
    Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children.   
Principal Investigator(s)
1. Robert Bandsma
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast General Hospital (Mombasa county)
3. Mbagathi Hospital (Nairobi City county)
4. Migori County Hospital (Migori county)
 
08-06-2021 View

167.

ECCT/20/12/03   CALINA STUDY
    A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.   Study number: CCOA566B2307   
Principal Investigator(s)
1. Benhards Ragama Ogutu
Site(s) in Kenya
KEMRI-Centre for Clinical Research (CCR)
 
08-03-2021 View

168.

ECCT/21/02/01   PTSD 102 TONIX
    A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308).   
Principal Investigator(s)
1. Prof. Lukoye Atwoli
Site(s) in Kenya
1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county)
2. KEMRI Nairobi (Nairobi City county)
3. Aga Khan University Hospital (Nairobi City county)
 
16-06-2021 View

169.

ECCT/20/10/04   yellow fever vaccine CVIA 079
    A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079.   
Principal Investigator(s)
1. Dr. Deborah Langat
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
28-12-2020 View

170.

ECCT/20/09/02   BEe-HIVe
     B-ENHANCEMENT OF HBV VACCINATIONIN PERSONS LIVING WITH HIV (BEe-HIVe) EVALUATION OF HEPLISAV-B,A5379   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
27-11-2020 View